Log in

NASDAQ:SMMT - SUMMIT THERAPEU/S Stock Price, Forecast & News

$1.58
-0.06 (-3.66 %)
(As of 12/13/2019 08:16 AM ET)
Today's Range
$1.50
Now: $1.58
$1.65
50-Day Range
$1.45
MA: $1.59
$1.76
52-Week Range
$1.10
Now: $1.58
$2.46
Volume65,116 shs
Average Volume26,153 shs
Market Capitalization$50.72 million
P/E Ratio1.88
Dividend YieldN/A
Beta1.18
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.50 million
Cash Flow$1.08 per share
Book Value$4.08 per share

Profitability

Net Income$9.99 million
Net Margins-1,432.73%

Miscellaneous

Employees61
Market Cap$50.72 million
Next Earnings DateN/A
OptionableOptionable

Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.


SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions

What is SUMMIT THERAPEU/S's stock symbol?

SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."

How were SUMMIT THERAPEU/S's earnings last quarter?

SUMMIT THERAPEU/S (NASDAQ:SMMT) posted its quarterly earnings data on Friday, October, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. The firm earned $0.15 million during the quarter, compared to analysts' expectations of $0.43 million. SUMMIT THERAPEU/S had a negative return on equity of 61.73% and a negative net margin of 1,432.73%. View SUMMIT THERAPEU/S's Earnings History.

What price target have analysts set for SMMT?

2 brokerages have issued 12-month price targets for SUMMIT THERAPEU/S's shares. Their forecasts range from $2.00 to $2.00. On average, they expect SUMMIT THERAPEU/S's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.

What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.

Has SUMMIT THERAPEU/S been receiving favorable news coverage?

News coverage about SMMT stock has trended somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for SUMMIT THERAPEU/S.

Who are some of SUMMIT THERAPEU/S's key competitors?

What other stocks do shareholders of SUMMIT THERAPEU/S own?

Who are SUMMIT THERAPEU/S's key executives?

SUMMIT THERAPEU/S's management team includes the folowing people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)
  • Ms. Michelle Avery, Director of Investor Relations

When did SUMMIT THERAPEU/S IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of SUMMIT THERAPEU/S?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SUMMIT THERAPEU/S's stock price today?

One share of SMMT stock can currently be purchased for approximately $1.58.

How big of a company is SUMMIT THERAPEU/S?

SUMMIT THERAPEU/S has a market capitalization of $50.72 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.View Additional Information About SUMMIT THERAPEU/S.

What is SUMMIT THERAPEU/S's official website?

The official website for SUMMIT THERAPEU/S is http://www.summitplc.com/.

How can I contact SUMMIT THERAPEU/S?

SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]


MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  532
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel